

# Better management of depression in cancer / Symptom Management Research Trials 3 Pilot

<b>Submission date</b> 27/11/2007	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 13/12/2007	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 01/08/2012	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Michael Sharpe

**Contact details**  
Psychological Medicine & Symptoms Research Group  
School of Molecular & Clinical Medicine  
University of Edinburgh  
Kennedy Tower  
Royal Edinburgh Hospital  
Edinburgh  
United Kingdom  
EH10 5HF

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
NA

# Study information

## Scientific Title

## Acronym

SMaRT 3 Pilot

## Study objectives

A pilot trial to:

- 1: Test the feasibility and acceptability of procedures
- 2: Obtain data to inform the sample size calculation for the SMaRT Oncology-3 Trial

SMaRT Oncology-3 Trial: A two-arm parallel group randomised controlled trial to determine the efficacy of adding a multi-component intervention for major depressive disorder to usual care compared to usual care alone in cancer patients who have a limited life expectancy.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Lothian Local Research Ethics Committee approval granted on 13 September 2007 (ref: 07/S1104/33)

## Study design

A two-arm parallel group randomised controlled pilot trial.

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Not specified

## Study type(s)

Not Specified

## Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

## Health condition(s) or problem(s) studied

Cancer, major depressive disorder

## Interventions

Usual care:

The patients' general practitioner and oncologist will be informed of their diagnosis of MDD. Patients will then receive the usual clinical management of depression as currently practised.

Usual care supplemented with "Depression Care for People with Cancer":  
In addition to the above Depression Care for People with Cancer will be implemented.

Components of Depression Care for People with Cancer:

1. Coordination of depression care and provision of information to all relevant health professionals
2. Brief psychological intervention for a maximum of ten sessions over a three-month period including education about depression and its management (behavioural activation and antidepressant medication) and problem-solving training
3. Monthly active follow-up by telephone for a further three-month period
4. Advice to general practitioner regarding the prescription of antidepressant medication

### **Intervention Type**

Other

### **Phase**

Not Specified

### **Primary outcome measure**

Acceptability and feasibility of the trial procedures

### **Secondary outcome measures**

The following data will be collected at baseline, 4, 8, 12, 16, 20 and 24 weeks:

1. Hopkin's Symptom Checklist Depression Scale (SCL-20)
2. European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30
3. EuroQuol-5D
4. Satisfaction with depression care item

### **Overall study start date**

03/12/2007

### **Completion date**

28/02/2008

## **Eligibility**

### **Key inclusion criteria**

1. Have a diagnosis of cancer
2. Be aged 18 or over
3. Be under specialist oncology care
4. Have a predicted survival, estimated by their cancer specialist, of between three and twelve months
5. Have symptoms which meet the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) criteria for Major Depressive Disorder (MDD) (using the inclusive approach to diagnosis)

### **Participant type(s)**

Patient

**Age group**

Adult

**Lower age limit**

18 Years

**Sex**

Both

**Target number of participants**

10-20

**Key exclusion criteria**

1. Unable to provide informed consent to participate
2. Episode of MDD is chronic (defined as a history of continuous depression for at least two years)
3. Judged to require urgent psychiatric care
4. Receiving active psychiatric or psychological treatment from specialist mental health services
5. Cognitive impairment or communication difficulties which are incompatible with the intervention
6. Known cerebral metastases
7. Unable to attend regularly for treatment sessions
8. Intervention is judged to be inappropriate due to a medical condition which requires alternative treatment
9. Intervention is judged to be inappropriate due to a psychiatric condition which requires alternative treatment (psychotic illness, bipolar affective disorder, obsessive compulsive disorder, substance abuse or dependence)
10. Participation in the trial is judged to be inappropriate on clinical grounds

**Date of first enrolment**

03/12/2007

**Date of final enrolment**

28/02/2008

**Locations****Countries of recruitment**

Scotland

United Kingdom

**Study participating centre**

Psychological Medicine & Symptoms Research Group

Edinburgh

United Kingdom

EH10 5HF

# Sponsor information

## Organisation

University of Edinburgh, Lothian Health Board, University Hospitals Division (UK)

## Sponsor details

c/o Dr Marise Bucukoglu  
Clinical Trials and Research Governance Manager  
College of Medicines and Veterinary Medicine  
The Queen's Medical Research Institute  
Edinburgh  
Scotland  
United Kingdom  
EH16 4TJ  
+44 (0)131 242 9262  
mbrown11@miscorp.ed.ac.uk

## Sponsor type

Hospital/treatment centre

## Website

<http://www.ed.ac.uk/>

## ROR

<https://ror.org/01nrxf90>

# Funder(s)

## Funder type

Charity

## Funder Name

Cancer Research UK (ref: C5547/A7375)

## Alternative Name(s)

CR\_UK, Cancer Research UK - London, CRUK

## Funding Body Type

Private sector organisation

## Funding Body Subtype

Other non-profit organizations

## Location

United Kingdom

# Results and Publications

Publication and dissemination plan  
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary  
Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/09/2009		Yes	No